Not Yet RecruitingNot Applicable

Benefit of High-flow Nasal Cannula on Persistent Dyspnea in Ild

42 participantsStarted 2024-10-15

Plain-language summary

The main purpose of this study is to evaluate the effects of high-flow nasal therapy (HFNT) oxygen compared to long-term oxygen therapy (LTOT) on dyspnea and quality of life in intersititial lung disease patients with chronic respiratory failure and persistent breathlessness in whom LTOT has already been initiated.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Intertitial lung disease * Persistant dyspnea (mMRC≥3) * Long-term oxygen therapy at least for 3 months Exclusion Criteria: * Chronic respiratory disease (COPD, lung cancer) * Pneumothorax, * Pneumomediastinum, * Active smoker, * Patient on non-invasive ventilation or continuous positive airway pressure (CPAP), * Pregnancy or breastfeeding, * Unable to read or understand questionnaires, * No written consent, * Patients under guardianship, * No health assurance coverage

What they're measuring

SGRQ questionnaire : Saint George's Respiratory Questionnaire (symptom component)

Timeframe: 2 weeks

Trial details

NCT IDNCT06617078

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-15

Contact for this trial

Capucine Morélot-Panzini, MD,PhD, Prof

0142167771 capucine.morelot@aphp.fr

View on ClinicalTrials.gov More ILD trials